160 results on '"Hirashima, Yasuyuki"'
Search Results
2. Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis
3. Microsatellite instability is biased in Amsterdam II-defined Lynch-related cancer cases with family history but is rare in other cancers: a summary of 1000 analyses
4. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary
5. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy
6. Quality of care measurement for patients with ovarian cancer in Japan.
7. Pathogenic Mechanisms of Venous Thromboembolism in Ovarian Tumor Patients
8. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
9. Activation of oxidative phosphorylation in TP53-inactive endometrial carcinomas with a poor prognosis
10. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)
11. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases
12. Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer
13. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial
14. Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome
15. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
16. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy
17. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
18. Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan
19. Clinicopathologic features of brain metastases from gynecologic malignancies: A retrospective study of 139 cases (KCOG-G1001s trial)
20. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: A Kansai Clinical Oncology Group study
21. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule
22. Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial
23. Feasibility of extended-field irradiation and intracavitary brachytherapy combined with weekly cisplatin chemosensitization for IB2–IIIB cervical cancer with positive paraaortic or high common iliac lymph nodes: a retrospective review
24. Characterization of rare histological subtypes of ovarian cancer based on molecular profiling.
25. Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer
26. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
27. Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer
28. Intraoperative evaluation of myometrial invasion and histological type and grade in endometrial cancer: diagnostic value of frozen section
29. A patient with stage 1a endometrial carcinoma in whom a solitary recurrent lesion was detected in the external iliac lymph node after MPA therapy
30. Internalization of urinary trypsin inhibitor in human uterine fibroblasts
31. The Protease Inhibitor Bikunin, a Novel Anti-Metastatic Agent
32. Identification of Link Protein during Follicle Development and Cumulus Cell Cultures in Rats
33. A multi-institutional survey of the quality of life after treatment for uterine cervical cancer: a comparison between radical radiotherapy and surgery in Japan.
34. Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis.
35. Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.
36. The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.
37. Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.
38. The relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer.
39. Feasibility and Acute Toxicity of Concurrent Chemoradiotherapy (CCRT) With High-Dose Rate Intracavitary Brachytherapy (HDR-ICBT) and 40-mg/m2 Weekly Cisplatin for Japanese Patients With Cervical Cancer.
40. Properties of a bifunctional chelating resin containing aminomethylphosphonate and sulfonate derived from poly(ω-bromobutylstyrene-co-divinylbenzene) beads
41. Identification of tumor microenvironment-associated immunological genes as potent prognostic markers in the cancer genome analysis project HOPE.
42. Transforming Growth Factor-β1 Produced by Ovarian Cancer Cell Line HRA Stimulates Attachment and Invasion through an Up-regulation of Plasminogen Activator Inhibitor Type-1 in Human Peritoneal Mesothelial Cells.
43. Human myometrial cells in culture express specific binding sites for urinary trypsin inhibitor.
44. Identification and characterization of a Kunitz-type protease inhibitor in ascites fluid from patients with ovarian carcinoma.
45. Microbiology of Pelvic Lymphocyst Infection after Lymphadenectomy for Malignant Gynecologic Tumors.
46. Serological and Immunohistochemical Diagnosis of Amniotic Fluid Embolism.
47. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
48. Erratum to: “Properties of a bifunctional chelating resin containing aminomethylphosphonate and sulfonate derived from poly(ω-bromobutylstyrene-co-divinylbenzene) beads” [Reactive & Functional Polymers 69 (2009) 828–835]
49. Identification and characterization of the cell-associated binding protein for urinary trypsin inhibitor
50. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.